Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof
WO2010028672A1
Use of a peptide as a therapeutic agent
WO2009033816A2
Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
AU2008297524A1
Use of Thymopentin as a therapeutic agent
WO2009033798A1
Combination of motilin and minigastrin as a therapeutic agent
WO2010028671A1
Use of opiorphin as a therapeutic agent
WO2009043521A2
Use of urocortin iii and urocortin i as therapeutic agents
WO2009046874A1
Therapeutic combination of trh-potentiating peptide and stresscopin
EP2187918A2
Combination of splenopentin and thymopentin and the use thereof in medicine
AU2008303893A1
Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
WO2009043523A2
Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
WO2009033807A2
Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
WO2009043526A2
Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent
WO2010028673A1
Use of a peptide as a therapeutic agent
EP2187938A2
Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent
